Waiv Secures $33M to Revolutionize Cancer Testing with AI

business #ai 📝 Blog|Analyzed: Mar 12, 2026 16:19•

Published: Mar 12, 2026 16:15

•

1 min read

Analysis

Waiv's spin-off from Owkin is a testament to the growing power of AI in healthcare. This funding will fuel their mission to enhance cancer testing precision, potentially leading to earlier and more effective diagnoses. The promise of using AI to improve patient outcomes is incredibly exciting!

Key Takeaways

•Waiv is a spin-off from the AI diagnostics and drug discovery platform, Owkin.
•The company is based in Paris and focuses on using AI to improve cancer testing.
•The funding round totals $33 million, showing significant investor confidence.

Reference / Citation

View Original

"Paris-based Waiv, which uses AI to enable more precise testing of cancer, raised $33M after spinning out of AI diagnostics and drug discovery platform Owkin"

TechmemeMar 12, 2026 16:15

* Cited for critical analysis under Article 32.

Older

Google Maps Revolutionized: Conversational AI and 3D Navigation Arrive!

Newer

Anthropic's Claude Unveils Chart Generation Feature in Beta: Visualizing Conversations